Patent ID: 11912780
Assignee: ACTINIUM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. The method of claim 8, wherein the radiolabeled BC8 is 131I-BC8, and the effective amount of 131I-BC8 is selected from the group consisting of from 10 mCi to 200 mCi administered 6, 7, or 8 days before performing the genetically edited hematopoietic stem cell therapy on the subject to treat the non-cancerous disorder, from 200 mCi to 400 mCi administered 8, 9, 10, 11, or 12 days before performing the genetically edited hematopoietic stem cell therapy on the subject to treat the non-cancerous disorder, and from 400 mCi to 1,200 mCi of 131I-BC8 administered 10, 11, 12, 13, or 14 days before performing the genetically edited hematopoietic stem cell therapy on the subject to treat the non-cancerous disorder.